Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01432405 · ClinicalTrials.gov registry record · Phase 4
Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes
A Phase 4 study of Type 2 Diabetes Mellitus, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01432405 is a Phase 4 study of Type 2 Diabetes Mellitus that has completed, run by Baylor College of Medicine. The registered enrollment target is 24 participants, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01432405, a Phase 4 study of Type 2 Diabetes Mellitus, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the effect of exenatide, an anti-diabetes medication, on liver fat and blood levels of proteins that influence liver fat.
Conditions Studied
Interventions
- DRUG Pioglitazone
- DRUG Exenatide
Study Locations (1)
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01432405
The ClinicalTrials.gov registry entry for NCT01432405 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Pioglitazone is the first listed.
NCT01432405 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01432405 about?
NCT01432405 is a clinical study titled "Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes". The purpose of this study is to examine the effect of exenatide, an anti-diabetes medication, on liver fat and blood levels of proteins that influence liver fat.
What is the current status of trial NCT01432405?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2007-06. Estimated completion is 2009-06.
What conditions does trial NCT01432405 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT01432405?
The interventions under investigation include: Pioglitazone (DRUG), Exenatide (DRUG).
Who is sponsoring clinical trial NCT01432405?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01432405 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism
ACTIVE NOT RECRUITING · Phase 4
-
Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?
COMPLETED · Phase 4
-
Adding Liraglutide to High Dose Insulin: Breaking the Cycle
COMPLETED · Phase 4
-
Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
COMPLETED · Phase 4
-
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
COMPLETED · Phase 4
-
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.